Pathogenic noncoding variants in the neurofibromatosis and schwannomatosis predisposition genes by Perez‐Becerril, Cristina et al.
Human Mutation. 2021;1–21. wileyonlinelibrary.com/journal/humu | 1
Received: 25 March 2021 | Revised: 16 June 2021 | Accepted: 13 July 2021
DOI: 10.1002/humu.24261
R EV I EW
Pathogenic noncoding variants in the neurofibromatosis and
schwannomatosis predisposition genes
Cristina Perez‐Becerril | D. Gareth Evans | Miriam J. Smith
Division of Evolution and Genomic Science,
Manchester Centre for Genomic Medicine, St
Mary's Hospital, Manchester Academic
Health Science Centre, School of Biological
Sciences, University of Manchester,
Manchester, UK
Correspondence
Miriam J. Smith, Division of Evolution and
Genomic Science, Manchester Centre for
Genomic Medicine, St Mary's Hospital,
Manchester Academic Health Science Centre,
School of Biological Sciences, University of
Manchester, Manchester M13 9WL, UK.
Email: miriam.smith@manchester.ac.uk
Funding information
U.S. Army Medical Research Acquisition
Activity (USAMRAA), Congresionally Directed
Medical Research Program (CDMRP),
Neurofibromatosis Research Program (NFRP),
Grant/Award Number: W81XWH1910334;
Manchester National Institute for Health
Research (NIHR) Biomedical Research Centre,
Grant/Award Number: IS‐BRC‐1215‐20007
Abstract
Neurofibromatosis type 1 (NF1), type 2 (NF2), and schwannomatosis are a group of
autosomal dominant disorders that predispose to the development of nerve sheath
tumors. Pathogenic variants (PVs) that cause NF1 and NF2 are located in the NF1
and NF2 loci, respectively. To date, most variants associated with schwannomatosis
have been identified in the SMARCB1 and LZTR1 genes, and a missense variant in
the DGCR8 gene was recently reported to predispose to schwannomas. In spite of
the high detection rate for PVs in NF1 and NF2 (over 90% of non‐mosaic germline
variants can be identified by routine genetic screening) underlying PVs for a pro-
portion of clinical cases remain undetected. A higher proportion of non‐NF2
schwannomatosis cases have no detected PV, with PVs currently only identified in
around 70%–86% of familial cases and 30%–40% of non‐NF2 sporadic schwanno-
matosis cases. A number of variants of uncertain significance have been observed
for each disorder, many of them located in noncoding, regulatory, or intergenic
regions. Here we summarize noncoding variants in this group of genes and discuss
their established or potential role in the pathogenesis of NF1, NF2, and
schwannomatosis.
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1 | INTRODUCTION
Neurofibromatosis type 1, type 2 (NF1, NF2), and non‐NF2
schwannomatosis, are a group of autosomal dominant genetic dis-
orders that predispose affected individuals to the development of
tumors in the nervous system and specifically on the nerve sheath.
Molecular characterization of these disorders has been important for
their accurate diagnosis and management, given the considerable
clinical phenotypic overlap, particularly between NF2 and non‐NF2
schwannomatosis. NF1 causative variants are located within the NF1
(chr17q11.2) gene (Cawthon et al., 1990; Shen et al., 1996; Viskochil
et al., 1990; Wallace et al., 1990) and hallmark features of the dis-
ease include predisposition to neurofibromas and the presence of
café‐au‐lait spots (CALS) (McGaughran et al., 1999). NF2 causative
variants are located within the NF2 locus (chr22q12.2) (Rouleau
et al., 1993; Trofatter et al., 1993) and predispose to bilateral ves-
tibular schwannomas, which are known to result in imbalance, tin-
nitus, and loss of hearing (Asthagiri et al., 2009). Other clinical
features of NF2 include cutaneous schwannomas, meningiomas, and
ependymomas (Evans et al., 1992; Smith et al., 2011). A large pro-
portion of NF2 patients die early as a result of the disease
(Hexter et al., 2015). Finally, SMARCB1‐ (chr22q11.23) and
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LZTR1‐ (chr22q11.21) associated schwannomatosis are character-
ized by the presence of non‐vestibular schwannomas that frequently
cause intractable pain (Hulsebos et al., 2007; Piotrowski et al., 2014).
Indeed, the absence of vestibular schwannomas has previously been
used as a diagnostic criterion to differentiate schwannomatosis from
NF2 (MacCollin et al., 2005), although there are reports of LZTR1‐
associated schwannomatosis patients with unilateral vestibular
schwannomas (Smith, Kulkarni, et al., 2012; Smith et al., 2015).
Genetic analysis is therefore useful and in many cases necessary to
resolve the diagnosis.
Pathogenic variants (PVs) leading to NF1 and NF2 are loss‐of‐
function (LoF) variants. Like other neoplastic syndromes, NF1 and
NF2 follow a two‐hit model whereby biallelic inactivation of the NF1
or NF2 gene precedes tumorigenesis (Knudson, 2001). However, the
full spectrum of mechanisms that lead to partial or total loss of
protein is yet to be established, as is the extent to which variation in
noncoding regions contributes to disease. Furthermore, the hetero-
geneity of phenotypes across patients has led to the proposal of a
possible role for modifying loci contributing to NF1 and NF2 pa-
thogenesis (Bruder, Ichimura, et al., 1999; Easton et al., 1993;
MacCollin et al., 2001; Pemov et al., 2014; Sharafi & Ayter, 2018; Yu
et al., 2020), thus increasing the interest in variants potentially af-
fecting regulatory regions.
The genetic profile of non‐NF2 schwannomatosis is hetero-
geneous and although associated variants result in at least partial
LoF, they do not always lead to loss of protein. In the case of
SMARCB1, for example, germline variants leading to schwannoma-
tosis tend to produce a protein with reduced functionality compared
to the wild type protein (Boyd et al., 2008; Smith, Walker, et al.,
2012; Smith et al., 2014) and loss of SMARCB1 protein in schwan-
nomas (either total or partial) has been shown to happen only in a
subset of cells (Patil et al., 2008). In addition, the mechanisms in-
volved in tumorigenesis in schwannomatosis appear to be more
complex than the two‐hit model described for NF1 and NF2, with
somatic biallelic inactivation of NF2 observed in tumors of patients
carrying SMARCB1 and LZTR1 germline mutations (Hadfield et al.,
2008; Paganini, Sestini, et al., 2015; Piotrowski et al., 2014; Sestini
et al., 2008). This seems to be true also for sporadic schwannoma-
tosis cases where inactivating somatic SMARCB1 and NF2 variants
were identified (Paganini et al., 2018). A recent report adds to this
complexity by suggesting a prominent role of microRNAs (miRNAs)
in schwannoma formation. Rivera et al. (2020) identified a novel
mutation in DGCR8, a microprocessor gene, in a family affected by
multinodular Goitre and schwannomatosis. This single nucleotide
variant (NM_022720.6:c.1552G>A) results in a change in amino acid
residue in position 518 of the protein, from glutamate to lysine
(p.Glu518Lys).
The continuous development of more sensitive and cost‐
effective methods to identify rare genetic variants associated with
disease has made it possible to identify an increasing number of
variants of uncertain significance (VUS). Many of these variants are
located in noncoding, regulatory, or intergenic regions and although
evidence is still limited, proposed mechanisms are emerging that
might explain their role in tumorigenesis. This might be illustrated by
newly discovered VUS predicted to affect splicing, which are of in-
terest given the role of aberrant splicing in tumorigenesis and me-
tastasis in NF2‐associated tumors (Koga et al., 1998; Luo et al., 2015;
Scoles et al., 1998) and the suggestion that alternative splicing may
account for at least some of the phenotype variability observed in
NF1 (Barron & Lou, 2012).
In addition to splicing variants, variants affecting cis‐regulatory
elements (CREs) have been proposed not only as drivers for disease
but also as modulators of penetrance and phenotype, suggesting the
possibility of as yet unidentified epistatic interactions between loci.
Examples of communication between different regulatory loci in-
clude reports of intronic sequences within certain genes that interact
with enhancers and regulate transcription of downstream or up-
stream targets (Stadhouders et al., 2012). Furthermore, intronic re-
gions may contain noncoding RNA transcripts that regulate gene
expression and may be relevant to carcinogenesis (Williams &
Farzaneh, 2012; Zimta et al., 2020).
The present review aims to summarize the different types of
noncoding variants in NF1, NF2, SMARCB1, and LZTR1 that have been
associated with disease and to integrate this data to provide an
overview of the implications for future characterization and diag-
nosis of these disorders.
1.1 | Coding mutation spectra
1.1.1 | Neurofibromatosis type 1
The NF1 (neurofibromin 1) gene spans approximately 300 kilobases
(kb) of chromosome 17q11.2 and encodes neurofibromin, which
negatively regulates the Ras pathway, through its GAP‐related do-
main (GRD). This is thought to be the main mechanism through which
neurofibromin exerts its tumor suppressor function (Bollag et al.,
1996; Danglot et al., 1995; Dischinger et al., 2018; Y. Li et al., 1995;
Marchuk et al., 1991; Martin et al., 1990). Two major isoforms of NF1
have been identified, containing 57 and 58 exons respectively
(Figure 1a). Regions of high homology with other members of GTPase
activating protein (GAP) family exist between exons 21 and 27a (Y. Li
et al., 1995; G. F. Xu et al., 1990). In addition, three smaller genes are
located within intron 26; OGMP (oligodendrocyte myelin glycopro-
tein), EVI2A (ecotropic viral integration 2A), and EVI2B (ecotropic viral
integration 2B) (Cawthon et al., 1990, 1991; Hinks et al., 1995).
Identification of genetic variants leading to NF1 associated
phenotypes has been cumbersome, in part due to the large size of
the NF1 locus. Moreover, a large proportion of germline PVs that
have been observed in NF1 patients are de novo, consistent with the
high de novo mutation rate of the gene (Evans et al., 2010; Messiaen
et al., 2000). The most common deleterious variants associated with
NF1 are those resulting in premature stop codons (Fahsold et al.,
2000). The second most common type of variant affects messenger
RNA (mRNA) splicing. Interestingly, these variants also constitute a
large proportion of the recurrent PVs observed across NF1 patients
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(Ars et al., 2003). Finally, a number of pathogenic missense variants
have been identified in NF1, primarily localized within two regions:
the GRD domain and a region starting on exon 11 and extending to
the cysteine‐serine‐rich domain (CSRD) of the gene (Assunto et al.,
2019; Fahsold et al., 2000; Koczkowska et al., 2018).
Genotype‐phenotype correlations of NF1‐associated variants
are scarce but those that have been established seem to point to
mild phenotypes associated with most missense variants, whereas
deletions (particularly large ones) tend to produce a more severe
phenotype (Kang et al., 2020; Kehrer‐Sawatzki, Mautner, et al., 2017;
Pinna et al., 2015; Rojnueangnit et al., 2015; Upadhyaya et al., 2007).
Notable exceptions to this trend are missense variants affecting
particular amino acid residues within mutational hotspots in neuro-
fibromin, namely the CSRD (codons 844‐848), the tubulin‐binding
(TB) domain (codon 1149), and the GRD (codons 1276 and 1423)
regions, which have been found to lead to a severe NF1 phenotype
(Koczkowska et al., 2018, 2020).
1.1.2 | Neurofibromatosis type 2
The NF2 gene (neurofibromin 2), located at chr22q12.2, codes for
the protein, merlin (moesin‐ezrin‐radixin‐like protein) (Trofatter





F IGURE 1 Schematic representation of major isoforms for the NF1, NF2, SMARCB1, and LZTR1 genes. (a) Major isoforms of NF1 (isoform 1
and isoform 2). While isoform 2 is the predominant transcript expressed in most tissue, isoform 1 is the most abundant form in central nervous
system (Andersen et al., 1993). Isoform 2 has been found to be overexpressed in primary brain tumors (Suzuki et al., 1991). Functional domains
are indicated as CSRD (cysteine–serine‐rich domain), TBD (tubulin‐binding domain), GRD (GAP‐related domain), Sec. 14 (Sec. 14‐like lipid‐
binding domain), PH (pleckstrin homology domain), HLR (HEAT‐like repeat regions), CTD (carboxy‐terminal domain), NLS (nuclear localization
signal region) and SBD (syndecan binding domain). (b) Two major isoforms of NF2; isoform 1, which skips exon 16, and isoform 2, in which
inclusion of exon 16 causes a reading frame shift and a slightly shorter protein product. The FERM and α‐helical domains are indicated. Both
merlin isoforms (1 and 2) are expressed in similar proportions across different cell types, with isoform 2 the slightly more abundant of the two
(Chang et al., 2002). (c) Two major isoforms of SMARCB1 (isoform 1 and isoform 2), expressed in almost equal proportion (45% and 50%,
respectively) across different tissues (Favre et al., 2003). Functional domains are indicated as DNABD (DNA binding domain), MYCBD (MYC‐
binding domain) and CTD (c‐terminal domain). (d) Main known isoform of LZTR1. Kelch and Broad‐complex, tramtrack, and bric‐à‐brac (BTB)
domains are indicated. Tissue‐specific expression values from GTEx project (GTEx Consortium, 2020) are included for available transcripts
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both mRNAs sharing the same sequence from exons 1–15 but dif-
fering at the last exon (Figure 1b). Isoform 1 contains exon 17 and
yields a 595 amino acid protein, whereas isoform 2 contains exon 16
and has a 590 amino acid product (Bianchi et al., 1994). Both of these
isoforms contain the N‐terminal FERM (4.1 ezrin, radixin, moesin)
domain, which is highly conserved among ERM family proteins and
has an important role in cell adhesion, motility, and signaling (Chishti
et al., 1998). Like other proteins containing a FERM domain, merlin
has a well‐established role in tumor suppression although the me-
chanisms involved appear to be different for merlin, compared to
other proteins within the ERM family (Cui et al., 2019; Petrilli &
Fernandez‐Valle, 2016).
A large proportion of germline PVs in NF2 are truncating var-
iants. These include nonsense, frameshift, and some splice‐site var-
iants that have traditionally been associated with a severe NF2
phenotype (higher tumor burden) while PVs resulting in a mutant
protein product (missense variants, in‐frame deletions, and some
splice‐site variants), as well as whole‐gene deletions, are associated
with a milder phenotype (Evans, 2009; Halliday et al., 2017;
Ruttledge et al., 1996). The location of the variant also seems to be of
importance, with splicing variants affecting exons on the 5′‐end of
the gene generating a more severe phenotype than those affecting
exons closer to the 3′‐end of the gene (Baser et al., 2005).
1.1.3 | Schwannomatosis
The considerable clinical overlap between NF2 and non‐NF2
schwannomatosis has caused a constant challenge in differentiating
these two disorders (Evans et al., 2018). However, a large number of
non‐NF2 schwannomatosis cases are attributable to two genes, both
located in close proximity to the NF2 gene. The first, SMARCB1 (SWI/
SNF related, matrix associated, actin‐dependent regulator of chro-
matin, subfamily b, member 1), is located in chromosome 22q11.23
(Boyd et al., 2008; Hadfield et al., 2008; Hulsebos et al., 2007; Sestini
et al., 2008; Smith, Wallace, et al., 2012). The second, LZTR1 (leucine
zipper‐like transcription regulator 1), is found at 22q11.21 and has
been linked to a proportion of schwannomatosis cases involving
vestibular schwannomas, which led to changes to the recommended
diagnostic criteria for NF2 and schwannomatosis (Piotrowski et al.,
2014; Smith et al., 2015, 2017). A third schwannomatosis candidate
gene, DGCR8 (DGCR8 microprocessor complex subunit), located in
chromosome 22q11.21 has emerged recently in one kindred
affected by schwannomatosis and euthyroid multinodular goiter
syndrome (Rivera et al., 2020). A germline missense variant
NM_022720.6:c.1552G>A (p.Glu518Lys) in the DGCR8 gene was
identified in six members of the family. This variant, designated
E518K in the original report, was predicted to reduce affinity of RNA
binding to DGCR8, resulting in reduced expression of miRNAs, as a
consequence of deficient cleavage of primary miRNAs (pri‐miRNAs)
to produce precursor miRNAs (pre‐mRNAs).
The type and location of PVs in the SMARCB1 gene have a
marked effect on phenotype. Genetic variants in SMARCB1 are
associated with several tumor predisposition disorders, including
malignant rhabdoid tumors (MRT), a condition that typically presents
during infancy and which has a poor prognosis. Although there have
been reports of families in which segregation of genetic variants in
SMARCB1 lead to MRT in some family members and schwannoma-
tosis in others, for the most part, these two conditions are distinct
both in clinical and genetic terms. While germline PVs associated
with schwannomatosis tend to be located at either extreme of the
gene and result in a hypomorphic transcript, truncating variants,
located around the central part of the gene, mostly lead to the de-
velopment of malignant rhabdoid tumors (Smith et al., 2014).
LZTR1 coding variants associated with schwannomatosis have
been identified across the full length of the gene including truncating
and non‐truncating variants. Several cases of incomplete penetrance
have also been observed for this gene (Hutter et al., 2014; Louvrier
et al., 2018; Paganini, Chang, et al., 2015; Paganini, Sestini, et al.,
2015; Piotrowski et al., 2014; Smith et al., 2015, 2017).
Together, PVs identified in SMARCB1 and LZTR1 account for
around 70%–86% of familial and 30%–40% of sporadic non‐NF2‐
associated schwannomatosis cases (Evans et al., 2018; Kehrer‐
Sawatzki, Farschtschi, et al., 2017). Only one PV in DGCR8
(NM_022720.6:c.1552G>A) has been discovered so far, pointing to
the existence of hitherto undiscovered causative genes and un-
discovered variant types within the known genes (Hutter et al., 2014;
Min et al., 2020; Rivera et al., 2020; Smith, Wallace, et al., 2012).
1.2 | Variants in the 5′‐untranslated region
(5′‐UTR)
The 5'‐UTR is known to harbor a number of elements that play an
important role in regulating protein translation (Hinnebusch et al.,
2016). Variants disrupting or potentially creating new upstream
open reading frames (uORFs) have been reported in both in NF1 and
NF2 although the mechanisms through which these variants may
contribute to disease etiology remain unclear (Evans et al., 2016;
Horan et al., 2004; Osborn et al., 2000; Whiffin et al., 2020). uORFs
are present in the 5′‐UTR of many protein‐coding genes and regulate
mRNA translation through three main mechanisms: (a) scanning may
start at upstream AUG (uAUG) and stop at a uORF stop codon,
triggering mRNA decay; (b) the uORF might be fully translated and
translation might be reinitiated at the downstream main ORF, al-
though this process is inefficient and usually results in lower protein
levels; (c) read‐through or leaky scanning may occur if the uAUG is
present without an in‐frame stop codon upstream the main ORF.
Regardless of the mechanisms involved, uORFs usually have in-
hibitory effects on protein translation (Calvo et al., 2009).
Variants in the 5′‐UTR of NF1 were reported in two early studies
aiming to identify and characterize variants disrupting regulatory ele-
ments (Horan et al., 2004; Osborn et al., 2000). By screening 570 NF1
patients and 105 unaffected controls, these reports identified 10 variants
within a 987 bp region upstream of the canonical translational start
AUG. Two of these variants NC_000017.11:g.31094851A>C and
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NC_000017.11(NM_000267.3):c.‐351G>C (originally annotated as A
+25C and G+132C, respectively) were located within uORFs, and further
characterization of these variants in vitro indicated that they were as-
sociated with slightly increased reporter gene activity compared to
wildtype constructs. An important caveat to these findings, noted by the
authors, is that these variants are rare and unlikely to affect phenotype
individually. However, the possibility remains that they collectively re-
flect disruptions in regulatory mechanisms that might be relevant for
disease.
This possibility is supported by more recent evidence. In an RNA
analysis study of 361 NF1 patients in Manchester data (Evans et al.,
2016) four likely disease‐causing variants (NC_000017.11
(NM_000267.3):c.‐280C>T, NC_000017.11(NM_000267.3):c.‐273A>C,
NC_000017.11 (NM_000267.3):c.‐272G>C, and NC_000017.11
(NM_000267.3):c.‐272G>A) were identified in the NF1 5′‐UTR region
in six affected individuals. Three of these changes (c.‐273A>C,
c.‐272G>C, and c.‐272G>A) involved two highly conserved nucleotides.
These variants were revisited more recently, by a large‐scale study using
data from over 15,000 individuals carrying loss‐of‐function variants ag-
gregated in the gnomAD database (Karczewski et al., 2020) providing
insight into the effects of uORF‐modifying variants on disease (Whiffin
et al., 2020), by demonstrating that two of the previously reported 5'‐
UTR variants (c.‐280C>T and c.‐272G>A) in NF1 create a new upstream
uAUG within strong and moderate Kozak consensus sites whilst the
other two (c.‐273A>C and c.‐272G>C) result in removal of the in‐frame
uORF stop codon.
This study also reported a novel variant, NC_000022.
11:g.29603933_29603934insT (NM_000268.3:c.‐66_‐65insT) in the
5′‐UTR of NF2, which creates an alternative uAUG with an in‐frame
stop codon just a few bases downstream. Notably, the insertion also
causes the reading frame of an existing uORF to shift so that it
overlaps with the canonical coding sequence. Either of these features
could cause downregulation of the canonical transcript. Interestingly,
the location of the existing uORF in the 5′‐UTR of NF2 seems to
coincide with an earlier report of a negative regulatory element in a
100 bp region upstream the start of the gene (Welling et al., 2000).
It is clear from these and other examples of variants disrupting
regulatory elements in 5′‐UTRs of cancer‐associated genes (Kutchko
et al., 2015; Somers et al., 2015) that further functional character-
ization is warranted to improve our understanding of their role in
tumor predisposition.
1.3 | Variants in the 3′‐UTR
Variants in the 3′‐UTR of NF1 and NF2 are rare and their relation to
pathogenicity is largely unknown (Ruttledge et al., 1996; Upadhyaya
et al., 1995). However, the variant, NC_000022.11:g.23834262C>T
(NM_003073.4:c.*82C>T), identified in the 3′‐UTR of SMARCB1 is
the most common recurrent schwannomatosis‐associated variant
(Smith et al., 2009; Smith, Wallace, et al., 2012). Further investigation
of possible mechanisms for disease associated with this variant re-
vealed reduced expression of the mutant allele (“T”) compared to the
wildtype allele and a negative effect on mRNA stability (Smith,
Walker, et al., 2012).
The role of 3′‐UTR regions in regulation of mRNA decay has
largely been attributed to the presence of binding sites for trans‐
acting factors, in particular miRNAs. Indeed, the role of miRNAs as
regulators of gene expression has long been studied in the context of
tumorigenesis and specifically in the context of NF1 (Amirnasr et al.,
2020; Sedani et al., 2012). Recently, some evidence of miRNA dys-
function associated with schwannomatosis has also been presented,
with the discovery of the missense variant in the DGCR8 gene
NM_022720.6:c.1552G>A (p.Glu518Lys) by Rivera et al. (2020).
Further characterization of this variant through analysis of schwan-
nomas and Wilms tumors with a DGCR8 mutant and loss of alternate
allele (p.Glu518Lys)/− genotype or a combined DGCR8 mutant and
wild type genotype (DGCR8(p.Glu518Lys)/wt) revealed a defined
group of miRNAs whose expression was significantly changed in
DGCR8(p.Glu518Lys)/− tumors compared to their DGCR8(p.Glu518-
Lys)/wt counterparts (Rivera et al., 2020). By comparing schwanno-
ma data to that of publicly available Wilms tumor datasets, the
authors propose a mechanism through which the DGCR8 p.Glu518-
Lys variant contributes to tumorigenesis, through disruption of
miRNA biogenesis mechanisms. However, elucidation of the role of
miRNAs in schwannomatosis and neurofibromatosis will likely de-
pend on identification of specific RNA‐binding factors and/or motifs
that may be relevant, given the large variety of cis‐ and trans‐acting
elements that exists whose function might be cell‐type or context‐
specific (Ray et al., 2013).
1.4 | Intronic and splicing variants
Intronic regions constitute a large proportion of the genome and play
an important role in regulation of gene expression by a number of
mechanisms (Rigau et al., 2019). While it is increasingly evident that
disruption of intronic sequences plays an important role in disease,
the identification and characterization of PVs within intronic regions
is more challenging than that of coding variants. The majority of
characterized PVs within intronic sequences have been identified
due to their disruption of splicing mechanisms. Many of these spli-
cing variants do not affect canonical splice sites and at least some of
them are deep intronic, located at least 10 bp into an intron
(Castellanos et al., 2013; De Klein et al., 1998). Around 3% and 1% of
variants in NF1 and NF2, respectively, are deep intronic (Castellanos
et al., 2013; Evans et al., 2016; Wallace et al., 2004). Identification
and characterization of deep intronic variants is only possible
through whole gene sequencing and RNA analysis. This makes them
less likely to be detected through current routing screening methods
for NF2 and schwannomatosis patients, for whom clinical genetic
testing is mainly based on DNA analysis.
Traditionally, transcription and splicing have been regarded as
sequential processes but there is evidence that they occur in
parallel and with considerable feedback between the processes
(Tellier et al., 2020). The implications of co‐transcriptional splicing
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might prove crucial to our understanding of splicing as an im-
portant mechanism for regulating gene expression at different
stages of development and in tumorigenesis (Eymin, 2020; Oltean
& Bates, 2014).
Alternatively spliced non‐pathogenic NF1, NF2, and SMARCB1
transcripts.
The identification of highly conserved alternative transcripts for
NF1 (Andersen et al., 1993; Bernards et al., 1992; Danglot et al.,
1994; Gutman et al., 1993; Kyritsis et al., 1992; Nishi et al., 1991;
Suzuki et al., 1992), NF2 (Bianchi et al., 1995; Chang et al., 2002;
Haase et al., 1994; Hara et al., 1994; Hitotsumatsu et al., 1994;
Lutchman & Rouleau, 1995; Pykett et al., 1994), and SMARCB1
(Bruder, Dumanski, et al., 1999; Favre et al., 2003) demonstrates the
relevance of alternative splicing in these genes (Figure 1). These
transcripts may be expressed in a tissue‐specific manner. Moreover,
in vitro and in vivo studies have shown that expression of some of
these isoforms is differentially regulated at distinct developmental
stages and that each isoform may have a specific function (Geist &
Gutmann, 1996; Gutmann et al., 1994, 1995, 1999; Hinman et al.,
2014; Hirvonen et al., 1998; Huynh et al., 1994; Jannatipour et al.,
2001; Mantani et al., 1994; Nguyen et al., 2017). This is reflected in
the differences observed in the expression profiles of NF1 isoforms
across different tumors (Danglot et al., 1995; Mochizuki et al., 1992;
Platten et al., 1996; Suzuki et al., 1991; Takahashi et al., 1994, 1995)
and, in the case of NF2, in the apparently exclusive role of tumor
suppressor for Merlin‐isoform 1, which some studies suggest, is not
replicated by isoform 2 protein. These changes in function have been
adjudicated to differences in sequence at the C‐terminal region re-
sulting in an inability to form interdomain associations (Mani et al.,
2011; Meng et al., 2000; Neill & Crompton, 2001; Sherman et al.,
1997), although this has been contested by more recent studies
(Laulajainen et al., 2012; Zoch et al., 2015).
1.4.1 | Pathogenic splicing variants
In NF1, NF2, SMARCB1, and LZTR1, PVs leading to splicing defects
are common, and many are recurrent (Ars et al., 2000, 2003; Ellis
et al., 2011; Messiaen et al., 2000; Piotrowski et al., 2014; Smith,
Walker, et al., 2012; Vandenbroucke et al., 2002). They are asso-
ciated with variable disease severity, a feature that has made their
characterization and classification more challenging (Kang et al.,
2020; Kluwe et al., 1998).
For the NF1 gene in particular, given its large size and the large
proportion of pathogenic intronic splice variants identified in people
with NF1 disease, clinical genetic testing is routinely carried out by
RNA analysis (Ars et al., 2000; Evans et al., 2016; Messiaen et al.,
2000; Upadhyaya et al., 2009). This is an important distinction in the
genetic testing of NF1 patients, compared to other hereditary dis-
orders, because it has allowed for identification of a higher propor-
tion of pathogenic variants that affect splicing, even when they are
not located in the canonical splicing sites. Pathogenic intronic var-
iants in NF1 include changes that disrupt the sequence of splice
donor or acceptor sites (Table S1) as well as those resulting in the
creation of new splicing sites (Table 1) or disrupting other intronic
regions of relevance to splicing. This is the case for variants resulting
in the creation of AG dinucleotides in the region between branch
point recognition sequences and their corresponding 3′ splice site
(3′ss), which have been shown to disrupt splicing by impeding re-
cognition of the AG from the 3′ acceptor site (Ainsworth et al., 1994;
Hatta et al., 1995; Wimmer et al., 2020).
Single base changes are the most common splicing variants re-
ported by these studies, followed by small deletions or insertions.
Interestingly, some of these variants have variable effects on tran-
scription and can lead to different phenotypes in individual carriers
with the same variant (Messiaen et al., 2000). An example of
this is the report of a variant, NC_000017.11(NM_000267.3):
c.5546+1G>C affecting the splice donor site in Exon 37 of NF1
(previously annotated as Exon 29) and resulting in skipping of either
exon 37 or exons 37 and 38 (Faravelli et al., 1999). The variant was
observed in DNA from the proband and the affected father, both of
whom lacked cutaneous features typical of NF1 so molecular analysis
was crucial for accurate diagnosis. In addition, Lisch nodules were
observed in the proband, but not in the affected father. A previous
study also identified alternative splicing of exons 37 and 38 (ori-
ginally annotated as exons 29 and 30) in a number of tissue samples
from NF1 patients, although no pathogenic variant was reported to
account for these isoforms (Park, Kenwright, et al., 1998). Ad-
ditionally, there are reports of the presence of nonsense (Ars et al.,
2000; Buske et al., 1999; Fahsold et al., 2000; Hatta et al., 1995;
Hoffmeyer et al., 1998; Messiaen et al., 1997, 2000; Pros et al., 2008;
Robinson et al., 1995; Sabbagh et al., 2013; Stella et al., 2018;
Upadhyaya et al., 1996; Valero et al., 2011; Wimmer et al., 2000,
2007; Zatkova et al., 2004) and missense (Ars et al., 2000, 2003;
Fahsold et al., 2000; Messiaen et al., 1999; Nemethova et al., 2013;
Osborn & Upadhyaya, 1999; Park & Pivnick, 1998; Pros et al., 2008;
Sabbagh et al., 2013; Stella et al., 2018; Upadhyaya et al., 1996;
Valero et al., 2011) variants resulting in exon skipping in the NF1
gene (Table 1). The cases of nonsense variants leading to splicing
defects seem to be rare for NF1, but are a well‐documented pathway
for alternative splicing. Exonic variants can cause alternative splicing
by disrupting exonic splicing enhancer (ESE) or exonic splicing si-
lencer (ESS) sites (Baralle et al., 2006; Colapietro et al., 2003; W. Xu
et al., 2014; Zatkova et al., 2004) as well as binding sites for splicing
factors (Skoko et al., 2008). Importantly, accurate classification for
many of these apparent nonsense and missense variants, as well as a
number of variants that would otherwise be designated VUS, as
splicing variants has only been possible through RNA analysis (Evans
et al., 2016; Messiaen et al., 2000).
Constitutional splice‐site variants in the NF2 gene have been
reported by a number of studies (Baser et al., 2004; Bijlsma et al.,
1994; Bourn et al., 1995; Dewan et al., 2017; Ellis et al., 2011; Evans
et al., 1998, 2005; Faudoa et al., 2000; Hagel et al., 2002; Jacoby
et al., 1994, 1996, 1999; Kluwe et al., 1996, 1998, 2000; Louvrier
et al., 2018; MacCollin et al., 1994; Mautner et al., 1996, 2002; Mérel
et al., 1995; Mohyuddin et al., 2002; Parry et al., 1996; Pemov et al.,
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2020; Rouleau et al., 1993; Ruttledge et al., 1996; Sadler et al., 2020;
Sainio et al., 2000; Seong et al., 2010; Sestini et al., 2000; Wallace
et al., 2004; Zemmoura et al., 2014). An interesting characteristic of
these variants is that they seem to give rise to heterogeneous phe-
notypes and their position in the gene has been reported to correlate
with severity of disease. Early studies appeared to suggest that
variants (including splicing variants) which preserved the C‐terminus
of the protein were associated with a milder phenotype (Mérel et al.,
1995). However, later studies have proposed that a severe
phenotype is more likely to be associated with an impaired ability of
merlin to form self‐associations, for which integrity of the N‐terminal
domain seems to be critical (Giovannini et al., 2000; Gutmann et al.,
1998). This led to the prediction that splicing PVs affecting the 3′ end
of the gene produce a milder phenotype than those located within
the first five exons (Baser et al., 2005). A summary of recurrent
splicing variants in NF2 is presented in Table 2.
Schwannomatosis‐associated variants disrupting consensus splice
sites in SMARCB1 (Boyd et al., 2008; Ding et al., 2019; Hadfield et al.,
TABLE 2 Recurrent germline splicing variants in patients with neurofibromatosis type 2
NF2 NC_000022.11 (NM_000268.3)
Variant Type of variant Splicing effect Identified in DNA/RNA Reports
c.115‐2A>G Splice acceptor site Skipping of exon 2 1DNA, 2RNA 1, 2
c.240+1G>T Splice donor site Predicted splice defect (exon 2) 3DNA & RNA, 1,4,5DNA, 1, 3, 4, 5
c.240+1G>C Splice donor site Predicted splice defect (exon 2) 5,6,7DNA 5,6, 7
c.241‐2A>G Splice acceptor site Predicted splice defect (exon 3) 5,7,8DNA 5, 7, 8
c.363+1G>A Splice donor site Predicted splice defect (exon 3) 9DNA, 10DNA & RNA 9, 10
c.447+1G>A Splice donor site Predicted splice defect (exon 4) 5,7,11DNA 5, 7, 11
c.447+2T>C Splice donor site Predicted splice defect (exon 4) 5,7DNA 5, 7
c.448‐1G>T Splice acceptor site Predicted splice defect (exon 5) 3,10DNA & RNA, 1,5,12,13DNA 1, 3, 5, 10, 12, 13
c.448‐1G>A Splice acceptor site Predicted splice defect (exon 5) 5,8,12,14DNA, 10DNA & RNA 5, 8, 10, 12, 14
c.448‐2A>G Splice acceptor site Predicted splice defect (exon 5) 5,6DNA, 10,15DNA & RNA 5, 6, 10, 15
c.448‐2A>T Splice acceptor site Predicted splice defect (exon 5) 6DNA, 15DNA & RNA 6, 15
c.516+1G>A Splice donor site Predicted splice defect (exon 5) 3,15DNA & RNA, 1,5,7DNA 1, 3, 5, 7, 15
c.600‐3C>G Splice acceptor site Predicted splice defect (exon 7) 5,14DNA 5, 14
c.600‐2A>G Splice acceptor site Predicted splice defect (exon 7) 5,7,14,16DNA 5, 7, 14, 16
c.675+5G>A Splice donor site Predicted splice defect (exon 7) 10,17DNA & RNA, 7,18DNA 7, 10, 17, 18
c.810G>A Splice donor site and synonymous
(E270E)
Predicted splice defect (exon 8) 4,19DNA 4, 19
c.1123‐2A>G Splice acceptor site Predicted splice defect (exon 12) 5,20DNA 5, 20
c.1340+1G>A Splice donor site Predicted splice defect (exon 12) 3DNA & RNA, 1,5DNA 1, 3, 5
c.1341‐1G>A Splice acceptor site Predicted splice defect (exon 13) 15DNA & RNA, 19DNA 15, 19
c.1341‐2A>C Splice acceptor site Del. 8 bp of 5′ side of exon 13 2RNA, 21DNA 2, 21
c.1447‐2A>G Splice acceptor site Skipping of exon 14 12,22DNA, 10DNA &
RNA, 2RNA
2, 10, 12, 22
c.1574+2T>C Splice donor site Skipping of exon 15 5,7DNA, 2RNA 2, 5, 7
c.1575‐1G>A Splice acceptor site Skipping of exon 15 10,15,23DNA & RNA, 2RNA 2, 10, 15, 23
c.1737G>T Missense (K579N) Skipping exon 15 12DNA, 10DNA & RNA, 2RNA 2, 10, 12
c.1737+1G>C Splice donor site Predicted splice defect (exon 15) 6,24DNA 6, 24
c.1737+3A>T Splice donor site Skipping of exon 15 and most of
exon 16
25DNA & RNA, 5DNA 5, 25
Reports: 1Merel et al. (1995); 2Ellis et al. (2011); 3Rouleau et al. (1993); 4Mohyuddin et al. (2002); 5Baser et al. (2004); 6MacCollin et al. (1994); 7Wallace
et al. (2004); 8Evans et al. (2005); 9Bijlsma et al. (1994); 10Kluwe et al. (1998); 11Sadler et al. (2020); 12Kluwe et al. (1996); 13Mautner et al. (2002);
14Evans et al. (1998); 15Parry et al. (1996); 16Kluwe et al. (2000); 17Jacoby et al. (1996); 18Hagel et al. (2002); 19Ruttledge et al. (1996); 20Bourn et al.
(1995); 21Dewan et al. (2017); 22Mautner et al. (1996); 23Faudoa et al. (2000); 24Sestini et al. (2000); 25Sainio et al. (2000).
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2008; Paganini, Sestini, et al., 2015; Smith, Walker, et al., 2012) lead to a
much less severe phenotype than SMARCB1 splice variants associated
with rhabdoid tumors. In general, schwannomatosis‐associated splice
variants lead to an in‐frame transcript with an exon, or part of an exon,
deleted. In contrast, rhabdoid tumor‐associated splice variants lead to
out‐of‐frame transcripts that are degraded by nonsense‐mediated decay.
However, a study of 14 schwannomatosis families provided some evi-
dence that splicing variants located towards the 3′‐end of SMARCB1may
be more likely to produce out‐of‐frame variants that can escape
nonsense‐mediated decay to some degree (Smith, Walker, et al., 2012).
Pathogenic splice variants have also been identified in LZTR1 in
schwannomatosis patients (Piotrowski et al., 2014; Smith et al., 2015).
Recurrent pathogenic splicing variants in LZTR1 have not been reported
so far, although the number of splice‐site variants and potentially splice‐
affecting variants continues to increase, especially in recent years with
studies re‐assessing previous diagnoses. An example of this is the
variant in the splice donor site of intron 8, NC_000022.11
(NM_006767.3):c.791+1G>A, was recently detected in peripheral lym-
phocytes and tumor tissue of a patient presenting solely with unilateral
vestibular schwannoma at age 14 (Gripp et al., 2017). A similar, more
recent study in patients with unilateral vestibular schwannoma
reported two VUS in LZTR1, NM_006767.3:c.1230C>T and NM_
006767.3:c.1687G>C, with the potential of affecting splicing, as pre-
dicted by in silico tools (Evans et al., 2019).
1.4.2 | Somatic splicing variants in schwannomas
Splicing variants in NF2 for NF2‐associated tumors and sporadic
schwannomas have been reported by several studies (Table S2). These
include a study that resulted in reclassification of patients diagnosed with
schwannomatosis who were more accurately diagnosed as having mosaic
NF2 (3/8 of cases without germline variants in NF2, LZTR1, or SMARCB1)
or LZTR1‐associated schwannomatosis (5/15 cases) after molecular
testing further highlighting the importance of genetic screening for ac-
curate diagnosis (Kehrer‐Sawatzki et al., 2018). Similarly, a more recent
study was able to classify a subset of patients with sporadic vestibular
schwannomas as mosaic NF2 (7/394) or schwannomatosis (5/394) cases
(Sadler et al., 2020). A notable finding from this study was the proportion
of somatic‐splicing variants in NF2 accounting for a “first hit” (38%).
Similarly, in their comprehensive approach for identification of germline
mutations and molecular characterization of NF1‐, NF2‐ and
schwannomatosis‐associated tumors Louvrier et al. (2018) have high-
lighted the importance of genetic testing and variant classification in
accurate diagnosis and clinical management of patients, particularly in
cases where clinical presentation overlaps two conditions, as is some-
times the case for the neurofibromatoses.
1.4.3 | Deep intronic variants
Intronic variants that do not disrupt canonical splice sites have also been
identified in NF1, NF2, and SMARCB1. In most cases, they affect splicing
by activation of cryptic splice sites. This was shown to be the case for the
deep intronic variant, NC_000017.11(NM_000267.3):c.5750‐279A>G, in
intron 38 of NF1 (originally designated c.31‐279A>G in intron 30). The
variant created a cryptic exon by generating a new 3′ splice site (ss) and
activating a weak 5′ ss, 172 nucleotides downstream of the variant
(Raponi et al., 2006). A similar mechanism was observed for
NC_000017.11(NM_000267.3):c.3198‐314G>A, reported in another
NF1 patient (Fernández‐Rodríguez et al., 2011). This variant, located in
intron 24 (previously 19a) of the NF1 gene, creates a new acceptor site
that activates two cryptic donor sites, resulting in two mutant transcripts
predicted to produce the same truncated protein (p.Asp1067Trpfs*7).
Interestingly, wildtype transcripts were also produced by the mutant
allele, presumably due to leaky scanning and leading to a mild phenotype
for the disease. Other deep intronic variants in NF1 have been identified
from large screening studies, although many of them remain un-
characterized (Ars et al., 2003; Evans et al., 2016; Fahsold et al., 2000;
Osborn & Upadhyaya, 1999; Perrin et al., 1996; Pros et al., 2008). Three
deep intronic variants that have been characterized were originally dis-
covered in a cohort of 374 unrelated NF1 patients (Pros et al., 2008).
These defects were subsequently reported to be corrected by antisense
morpholino oligomers (Pros et al., 2009). Overall, deep intronic splice
variants account for around 3% of all NF1 pathogenic germline variants
(Abernathy et al., 1997; De Luca et al., 2004; Evans et al., 2016; Hatta
et al., 1995; Messiaen et al., 2000; Nemethova et al., 2013; Upadhyaya
et al., 2009).
There is another less common, but notable, example of a deep
intronic variant in NF1, leading to aberrant splicing. This is a de novo
introduction of an Alu repeat element 44bp upstream of exon 41 of
the NF1 gene (NM_000267.3) that results in disruption of branch‐
point recognition and leads to skipping of the exon and loss of 771
amino acids on the C terminus of the protein. The authors compared
the repeat to other known members of the Alu family and found it to
be most similar to the most recently inserted human‐specific Alu
subfamily, whose members are reported to be polymorphic across
human populations, as well as transcriptionally active (Wallace et al.,
1991). Alu elements, along with other short interspersed nuclear
elements (SINE), are known to be important drivers of structural
variation and alternative splicing in the human genome (Huang et al.,
2010; Iskow et al., 2010). Previous studies have sought to determine
the extent to which SINE contribute to genetic variation in the NF1
gene and potentially to pathogenesis. One such study reports a
polymorphism associated with the presence of a L1 element in intron
30 of NF1 (Bleyl et al., 1994). Further, 18 L1 insertions, 14 of which
were Alu elements, have been identified in NF1, as part of a study
that provided evidence or intergenic regions susceptible to L1‐
endonuclease mediated retrotransposition (comprising exon 21–23
of the gene) and confirmed the role of Alu elements in alternative
splicing mechanisms in NF1 (Wimmer et al., 2011).
Deep intronic variants have also been found in the NF2 gene
(Castellanos et al., 2013; De Klein et al., 1998; Ellis et al., 2011; Hagel
et al., 2002; Jacoby et al., 1994, 1996; Kluwe et al., 1998; Ruttledge
et al., 1996; Wallace et al., 2004). De Klein et al. reported a single
nucleotide change, NC_000022.11(NM_000268.3):c.516+232G>A in
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intron 5, that results in generation of a consensus branch point se-
quence that, in turn, activates a cryptic exon (De Klein et al., 1998).
Interestingly, the authors report higher than expected amounts of
wildtype RNA in tumor tissue suggesting that the variant does not
fully impair normal splicing or perhaps that it is compensated by the
wild‐type allele. This observation is consistent with the mild pheno-
type observed in the affected family. More recently a study
reported a deep intronic variant in intron 13 of NF2 (NC_
000022.11(NM_000268.3):c.1447‐240T>A), which leads to the in-
clusion of a 167bp cryptic exon and produces a truncated merlin
protein (p.Pro482Profs*39) that results in a severe phenotype
(Castellanos et al., 2013). An assessment of the proportion of PVs
that are deep intronic is not possible outside of familial disease due
to the high rate of mosaicism in de novo cases. With a detection rate
of 96% for 165 s generation NF2 families only one of the seven
families with unfound variants after tests for large rearrangements,
chromosome translocations and 5′‐UTR variants had a deep intronic
variant (NC_000022.11 (NM_000268.3):c.516+232G>A) represent-
ing only 1/165 (0.6%) (unpublished data from Manchester Centre for
Genomic Medicine).
A deep intronic variant (NC_000022.11(NM_003073.4):
c.795+1498C>T) in intron 6 of SMARCB1 was also reported recently
in all affected members of a large schwannomatosis family. This
variant causes insertion of 94 nucleotides from intron 6, resulting in
premature termination of the transcript (Smith et al., 2020). The
association of this variant with schwannomatosis, rather than rhab-
doid tumors, lends further support to the theory that some residual
expression of this type of variant occurs or that enough normal
transcript is expressed to keep the effect hypomorphic.
It is important to note that identification and accurate char-
acterization of deep intronic variants, as well as splice‐altering sy-
nonymous and nonsense variants, has only been possible through
RNA analysis, since many of these variants are located at least 10bp
away from exon‐intron boundaries and would not be assessed by
exon screening techniques. This issue is illustrated by a large mRNA
study of NF1 in neurofibromatosis type 1 cases, for which ~12% of
variants (41/348) were deemed to be only classifiable through RNA
transcript analysis (Evans et al., 2016).
1.5 | Further role of CREs in neurofibromatosis
and schwannomatosis
The emerging knowledge of the mechanisms involved in regulation of
gene expression by CREs has been valuable for characterization of
noncoding variants associated with different types of cancer (Bailey
et al., 2016; Hayward et al., 2017; Hoang et al., 2018; K. Li et al.,
2020; Rheinbay et al., 2017; Vinagre et al., 2013; Zhou et al., 2020).
Conserved regions have provided clues to the identification of re-
levant CREs as well as binding sites for trans‐acting elements (Kelly
et al., 2015). An example of this is the highly homologous regions of
the NF1 GRD that have been observed in Ras proteins across species
(Bourne et al., 1990; Buchberg et al., 1990). Furthermore,
comparison of the full human and murine neurofibromin sequences
revealed a high degree of similarity (>98%) and high conservation
levels across 5′‐ and 3′‐UTRs (Bernards et al., 1993; Hajra et al.,
1994). A subsequent in silico study compared the 5′ upstream region
and intron 1 of NF1 and homologous genes in human, mouse, rat, and
puffer fish (Fugu rubripes). The authors found high homology seg-
ments throughout the region across all species, including two exact
matches and one near exact match in the 5′‐UTR, as well as one
exact match in intron 1. Along with these findings, they predict two
transcription start sites for NF1 and corresponding promoter re-
gions, despite not being able to identify a TATA box or any other
core promoter element (Lee & Friedman, 2005). Interestingly, an
independent study found that TATA‐box binding protein like 1
(TBPL1), interacts with the TATA‐less promoter region of NF1 and
drives its expression, both in humans and in mice (Chong et al.,
2005). This points to a mechanism of regulation distinct to that in-
volved in translation of TATA containing transcripts.
An early study comparing the open reading frame from human
NF2 with its mouse homologue found a high level of identity between
the two complementary DNA sequences including the 5′‐UTR and
promoter regions (Claudio et al., 1994). A later comparison of the full
NF2 gene across five species (human, baboon, mouse, rat, and puffer
fish) found highly conserved elements in exonic and extra‐exonic
sequences, including the promoter region. Notably, one such ele-
ment, inter 1, is conserved in all five organisms, and is located be-
tween the promoters of NF2 and NIPSNAP1 (Hansson et al., 2003). In
a follow up study the authors used DNA from 100 meningioma
samples and sequenced the same well conserved regions, including
non‐exonic regions. The study reported 39 alterations, one of them
located in the inter 1 region (NC_000022.11:g.29589068C>A), ap-
proximately 15 kb upstream of the NF2 promoter. However, the
relevance of this variant remains unclear since the meningioma in
which it was identified also contained a pathogenic frame‐shift var-
iant in exon 13 and presented monosomy of chromosome 22
(Hansson et al., 2007).
It has become increasingly evident that enhancers are an im-
portant component of the transcription regulatory machinery. These
elements interact with their targets in a conformation‐dependent
way and their function has an effect on, and is affected by, DNA
topology (Furlong & Levine, 2018; Rickels & Shilatifard, 2018). The
availability of large amounts of data on regulatory elements
throughout the genome, integrated through initiatives like the EN-
CODE project database (ENCODE Project Consortium, 2012), has
made it possible to examine in more detail the role of transcription
enhancers in the pathophysiology of NF1. An in silico analysis of
long‐range DNA‐DNA interactions predicted a number of DNA re-
gions interacting with the region containing NF1, defined in the study
as 17:29000000‐29999999 (GRCh37). Most interactions were ob-
served between the NF1 containing region and the adjacent region
spanning 17:28000000‐28999999. The combination of these find-
ings with ENCODE data also revealed each of these DNA fragments
contained a region enriched for H3K27ac, a histone recognized as a
marker for active enhancers. Sequencing of these H3K27ac‐rich
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regions in 47 unrelated NF1 patients identified three variants. One
of these novel single nucleotide changes, NC_000017.11:g.30519775
C>T, was present in two individuals. Although the effects of these
variants are still uncertain, the authors note that at least one of these
variants (NC_000017.11:g.30519865C>T) is located within over-
lapping transcription factor binding sites (Hamby et al., 2013).
No link between SMARCB1 or LZTR1 variants and disruption of
cis‐regulatory elements has been established so far. However, nor-
mal function of the SWI/SNF complex is intrinsically relevant to
promoter activation and is important for a wide range of signaling
mechanisms in numerous tissues. Complete loss of SMARCB1 pro-
tein has been mainly associated with the development of rhabdoid
tumors and has been shown to lead to aberrant SWI/SNF complex
formation in yeast (Sen et al., 2017). This has been supported by a
study which characterized the role of the SWI/SNF complex in en-
hancer function in rhabdoid tumor cell lines (Wang et al., 2017). This
study found that SMARCB1 was essential for stability of the SWI/
SNF complex and required for enrichment of the protein complex at
enhancers, thus mediating gene expression. Gene Ontology (GO)
analysis revealed that genes affected by loss of SMARCB1 were
mainly cell‐type specific, although those that were observed to be
dysregulated in all cell lines tend to be involved in regulation of cell
differentiation. Interestingly, SMARCB1 was not necessary for en-
richment of the SWI/SNF complex to super‐enhancers that may be
required for tumor growth.
2 | CONCLUDING REMARKS
Noncoding variants make up a significant proportion of pathogenic
variants identified in neurofibromatosis and schwannomatosis‐
associated genes. The great majority of these variants exert their
deleterious effect by producing changes in splicing, in many cases
through mechanisms that do not involve disruption of canonical
splice sites (Raponi et al., 2009; Wimmer et al., 2020).
In addition to splicing variants, the effect of CREs (and mutations
within them) on NF1, NF2, and non‐NF2 schwannomatosis genes
have been proposed not only as drivers for disease but also as
modulators of penetrance and phenotype, suggesting the possibility
of as yet unidentified epistatic interactions between loci (Kehrer‐
Sawatzki, Farschtschi, et al., 2017; Sabbagh et al., 2009). Commu-
nication between different regulatory loci might be relevant for in-
tronic regions as well. Stadhouders et al. present several examples of
intronic sequences within certain genes, that interact with enhancers
and regulate transcription of downstream or upstream targets
(Stadhouders et al., 2012). Intronic regions are also of interest be-
cause they may contain noncoding RNA transcripts that have a role
in regulation of gene expression that may be relevant to carcino-
genesis (Williams & Farzaneh, 2012; Zimta et al., 2020). This is a
particularly intriguing possibility in the context of the established
role of schwannomatosis‐associated genes, such as SMARCB1 and
DGCR8, in epigenetic mechanisms (Jung et al., 2020; Weissmiller
et al., 2019).
The relevance of noncoding variants to disease has been laid
bare by the fact that a large proportion of loci associated with
common disease, that have been identified by large GWAS stu-
dies, are not contained within the coding sequence (Albert &
Kruglyak, 2015). This points to the relevance of noncoding re-
gions as genetic factors for disease. An increasing number of
studies have reported variants located in intronic and regulatory
regions as causative of rare disorders (Johnston et al., 2019;
Vuckovic et al., 2020; Whiffin et al., 2020). Moreover, disruption
of regulatory mechanisms of gene expression is recognized as an
important factor in carcinogenesis (K. Li et al., 2020; Lowdon &
Wang, 2017; Orlando et al., 2018; Weinhold et al., 2014).
Furthermore, some studies have been able to define tumor sub-
types by the recurrent noncoding variants they carry, suggesting
the possibility of the use of epigenetic signatures in diagnosis and
treatment (Hayward et al., 2017; Torchia et al., 2016;
Wellenreuther et al., 1995)
The continuous development of tools for genomic analysis,
including long‐read sequencing, chromosome conformation cap-
ture (Hi‐C), and clustered regularly interspaced short palindromic
repeats (CRISPR) are rapidly increasing our understanding of the
mechanisms by which noncoding variants cause or modify disease
(Cumming et al., 2018; Hamby et al., 2013; Kremer et al., 2017;
Sanjana et al., 2016). In addition, large databases of genetic var-
iants, gene expression, and transcriptional regulation, such as
gnomAD (Karczewski et al., 2020), GTEX (GTEx Consortium,
2020), and ENCODE (ENCODE Project et al., 2020), will continue
to support the creation of better bioinformatics tools for appro-
priate clinical classification of VUS, particularly those located in
noncoding regions, and may also aid identification of the missing
heritability in neurofibromatosis and schwannomatosis (Evans
et al., 2010, 2018). Indeed, the availability of large whole‐exome
and whole‐genome sequencing datasets has made it possible to
calculate more accurate frequency estimates for rare variants that
can be used for prediction of their pathogenicity (Whiffin et al.,
2017). ACMG guidelines, used in interpretation and classification
of genetic variants, define five categories of variants as “patho-
genic,” “likely pathogenic,” “uncertain significance,” “likely benign,”
or “benign.” Variants are in turn assigned to each category on the
basis of specific criteria for which evidence is considered and
classified as very strong, strong, moderate, or supporting
(Richards et al., 2015). These guidelines also provide a framework
for integration of in silico predictive tools to use as evidence of
pathogenicity and this framework is continuously updated and
improved to produce a more robust methodology that provides
support for cascade testing of relatives (Ellard et al., 2020).
Better understanding of the mechanisms through which non-
coding variants lead to NF1, NF2, or schwannomatosis might
prove crucial for identification of novel causative variants and
possible new genes and loci associated with these disorders. This
in turn might contribute to more accurate diagnosis, clinical
management, and ultimately future therapeutics for these
disorders.
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